JP2007534772A - ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 - Google Patents

ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 Download PDF

Info

Publication number
JP2007534772A
JP2007534772A JP2007510987A JP2007510987A JP2007534772A JP 2007534772 A JP2007534772 A JP 2007534772A JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007534772 A JP2007534772 A JP 2007534772A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nos
group
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007510987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534772A5 (https=
Inventor
ガリー ローゼンバーグ，
ショーン ピー． イアドナト，
Original Assignee
イルミジェン バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イルミジェン バイオサイエンシーズ， インコーポレイテッド filed Critical イルミジェン バイオサイエンシーズ， インコーポレイテッド
Publication of JP2007534772A publication Critical patent/JP2007534772A/ja
Publication of JP2007534772A5 publication Critical patent/JP2007534772A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007510987A 2004-04-27 2005-04-27 ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 Pending JP2007534772A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56568804P 2004-04-27 2004-04-27
PCT/US2005/014668 WO2005104785A2 (en) 2004-04-27 2005-04-27 Methods and compositions for specifically targeting human hepatocellular carcinoma cells

Publications (2)

Publication Number Publication Date
JP2007534772A true JP2007534772A (ja) 2007-11-29
JP2007534772A5 JP2007534772A5 (https=) 2008-06-19

Family

ID=35242179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510987A Pending JP2007534772A (ja) 2004-04-27 2005-04-27 ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物

Country Status (4)

Country Link
US (1) US20080152650A1 (https=)
EP (1) EP1755669A4 (https=)
JP (1) JP2007534772A (https=)
WO (1) WO2005104785A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020189874A (ja) * 2017-08-25 2020-11-26 ストーク セラピューティクス，インク． 状態および疾患の処置のためのアンチセンスオリゴマー
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
US12577561B2 (en) 2019-02-27 2026-03-17 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
WO2008118176A2 (en) * 2006-06-02 2008-10-02 Verenium Corporation Lase enzymes, nucleic acids encoding them and methods for making and using them
EP2388338A1 (en) * 2010-04-30 2011-11-23 Medizinische Hochschule Hannover Method for determination of and medicament for influencing the activity of the immune system
CN114935651A (zh) * 2022-04-27 2022-08-23 广州源康生物医药科技有限公司 一种肿瘤生物标志物及应用
WO2024180461A1 (en) * 2023-02-27 2024-09-06 Ebrahiminik Hojat Integrated system for ethanol ablation and radiofrequency ablation of thyroid nodules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7549498A (en) * 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
EP1217066A1 (en) * 2000-12-21 2002-06-26 Universiteit Gent Modulation of ATP-binding cassette transporter activity
US20040068096A1 (en) * 2001-09-21 2004-04-08 Zenta Tsuchihashi Human single nucleotide polymorphisms in organic anion transport and multi-drug resistant proteins
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
CN1659287A (zh) * 2002-04-05 2005-08-24 美国政府健康及人类服务部 诊断肝癌转移或发病可能性及鉴定治疗靶点的方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020189874A (ja) * 2017-08-25 2020-11-26 ストーク セラピューティクス，インク． 状態および疾患の処置のためのアンチセンスオリゴマー
JP7420679B2 (ja) 2017-08-25 2024-01-23 ストーク セラピューティクス，インク． 状態および疾患の処置のためのアンチセンスオリゴマー
JP2024045199A (ja) * 2017-08-25 2024-04-02 ストーク セラピューティクス，インク． 状態および疾患の処置のためのアンチセンスオリゴマー
US12577561B2 (en) 2019-02-27 2026-03-17 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases

Also Published As

Publication number Publication date
EP1755669A4 (en) 2008-06-25
WO2005104785A2 (en) 2005-11-10
US20080152650A1 (en) 2008-06-26
WO2005104785A3 (en) 2006-05-26
EP1755669A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
JP5750433B2 (ja) 診断および治療のための腫瘍関連抗原の同定
US20220323478A1 (en) Agents for the treatment of diseases associated with undesired cell proliferation
US10894989B2 (en) Treatment of angiogenesis disorders
US20070092529A1 (en) Compositions and methods for diagnosing and treating cancers
EP4155404A1 (en) Blood-brain barrier penetrating aptamer, and use thereof
AU2023203737B2 (en) Methods for diagnosing and treating metastatic cancer
JP2007534772A (ja) ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物
US11576873B2 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2021078679A1 (en) Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets
CN113924364A (zh) 治疗亨廷顿病的组合物和方法
CN101522918A (zh) 用于治疗和诊断癌症及癌转移的组合物及方法
CN107106697B (zh) Pdgfr rna适体
KR20250131579A (ko) Itgav 표적 기반 항-혈관신생 요법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081022

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705